Drugs that contain Remdesivir

1. Drug name - VEKLURY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE46762 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(6 years from now)

US8318682 GILEAD SCIENCES INC 1′substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(6 years from now)

US8008264 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Sep, 2029

(6 years from now)

US10065958 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Sep, 2031

(8 years from now)

US9724360 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(13 years from now)

US9949994 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(13 years from now)

CN102046626A GILEAD SCIENCES INC Carba-Nucleoside Analogs For Antiviral Treatment
Sep, 2015

(7 years ago)

CN102015714B GILEAD SCIENCES INC 1'-Substitued Carba-Nucleoside Analog For Antiviral Therapy
Apr, 2029

(6 years from now)

CN102015714A GILEAD SCIENCES INC 1'-Substituted Carba-Nucleoside Analogs For Antiviral Treatment
Apr, 2029

(6 years from now)

CN104262345B GILEAD SCIENCES INC Antiviral Therapy For 1 ' - Substituted Carba-Nucleoside Nucleoside Analogues
Apr, 2029

(6 years from now)

CN104262345A GILEAD SCIENCES INC 1'-Substitued Carba-Nucleoside Analog For Antiviral Therapy
Apr, 2029

(6 years from now)

CN103052631B GILEAD SCIENCES INC Method And Composite For Treating Assistant Adhesive Virus Family Virus Infection
Jul, 2031

(8 years from now)

CN105343098A GILEAD SCIENCES INC Method And Composite For Treating Assistant Adhesive Virus Family Virus Infection
Jul, 2031

(8 years from now)

CN105343098B GILEAD SCIENCES INC For Treating Virus Virus Infection Of Secondary Method And Compound
Jul, 2031

(8 years from now)

CN103052631A GILEAD SCIENCES INC Method And Compound For Treating Paramyxoviridae Virus Infection
Jul, 2031

(8 years from now)

CN107073005A GILEAD SCIENCES INC Method Of Treating Filamentous Virus Family Virus Infections
Oct, 2035

(13 years from now)

CN107073005B GILEAD SCIENCES INC Method Of Treating A Virus Infection In A Filamentous Virus
Oct, 2035

(13 years from now)

IN289041B GILEAD SCIENCES INC Carba-Nucleoside Analogs For Antiviral Treatment
Apr, 2029

(6 years from now)

IN319927B GILEAD SCIENCES INC Methods And Compounds For Treating Paramyxoviridae Virus Infections
Jul, 2031

(8 years from now)

IN201301328P4 GILEAD SCIENCES INC Methods And Compounds For Treating Paramyxoviridae Virus Infections
Jul, 2031

(8 years from now)

EP2937350A1 GILEAD SCIENCES INC 1' -Substituted Carba-Nucleoside Analogs For Antiviral Treatment
Apr, 2029

(6 years from now)

EP2280973B1 GILEAD SCIENCES INC Carba-Nucleoside Analogs For Antiviral Treatment
Apr, 2029

(6 years from now)

EP2937350B1 GILEAD SCIENCES INC 1' -Substituted Carba-Nucleoside Analogs For Antiviral Treatment
Apr, 2029

(6 years from now)

EP2280973A1 GILEAD SCIENCES INC Carba-Nucleoside Analogs For Antiviral Treatment
Apr, 2029

(6 years from now)

EP2268642B1 GILEAD SCIENCES INC 1' -Substituted Carba-Nucleoside Analogs For Antiviral Treatment
Apr, 2029

(6 years from now)

EP2268642A1 GILEAD SCIENCES INC 1' -Substituted Carba-Nucleoside Analogs For Antiviral Treatment
Apr, 2029

(6 years from now)

EP2595980A1 GILEAD SCIENCES INC Methods And Compounds For Treating Paramyxoviridae Virus Infections
Jul, 2031

(8 years from now)

EP2595980B1 GILEAD SCIENCES INC Methods And Compounds For Treating Paramyxoviridae Virus Infections
Jul, 2031

(8 years from now)

EP3212175B1 GILEAD SCIENCES INC Methods For The Preparation Of Ribosides
Oct, 2035

(13 years from now)

EP3212174A1 GILEAD SCIENCES INC Methods For Treating Filoviridae Virus Infections
Oct, 2035

(13 years from now)

EP3212174B1 GILEAD SCIENCES INC Methods For Treating Filoviridae Virus Infections
Oct, 2035

(13 years from now)

EP3366295B1 GILEAD SCIENCES INC Methods For Treating Filoviridae Virus Infections
Oct, 2035

(13 years from now)

EP3366295A1 GILEAD SCIENCES INC Methods For Treating Filoviridae Virus Infections
Oct, 2035

(13 years from now)

EP3212175A1 GILEAD SCIENCES INC Methods For The Preparation Of Ribosides
Oct, 2035

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695361 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections Sep, 2036

(13 years from now)

US11007208 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections Sep, 2036

(13 years from now)

US10675296 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections Jul, 2038

(15 years from now)

Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg); treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription
100MG/20ML (5MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.